 |
 |
 |
 |
 |
 |
|
|
ABIOMED Home > News > Press Releases |
||||||||||||
 |
||||||||||||||
| ABIOMED ANNOUNCES FISCAL FIRST QUARTER 2007 RESULTS WITH REVENUES UP 55% TO $13 MILLION | ||||||||||||||
| Revenue
for Console Sales Grew 398%
DANVERS, Mass. (August 8, 2006)-Abiomed, Inc. (NASDAQ: ABMD) today announced financial results for its first fiscal 2007 quarter ended June 30, 2006. Revenue for the quarter was $13 million, up 55% compared to revenue of $8.4 million in the first quarter of fiscal 2006.
The Company is updating its revenue guidance for fiscal 2007 to $52 million, or approximately 20% growth, up from its previous guidance of a range between $49 million to $52 million. Financial information for the first quarter of fiscal 2007 is attached to this press release. CONFERENCE CALL AND WEBCAST INFORMATION Abiomed will host a conference call to discuss the first quarter results on August 8, 2006, at 5:00 p.m. ET. Michael R. Minogue, Chairman, Chief Executive Officer and President, and Daniel J. Sutherby, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via www.abiomed.com or dial 800-289-0494; the international number is 913-981-5520. A replay of this conference call will be available beginning at 8:15 p.m ET on August 8, 2006, through 11:59 p.m. ET Sunday, August 13, 2006. The replay phone number is 888-203-1112; the international number is 719-457-0820. The replay access code is 7544547. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, Abiomed offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other IMPELLA devices are not yet available for sale in the United States. The Company's AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com. www.abiomed.com. Contacts:
FORWARD-LOOKING STATEMENTS This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events. ###
|
||||||||||||||
